Original Article
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
N Engl J Med 2006; 354:131-140January 12, 2006
- Abstract
Background
Angiotensin-converting–enzyme inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency (serum creatinine level, 3.0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency.
Methods
We enrolled 422 patients in a randomized, double-blind study. After an eight-week run-in period, 104 patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years. All patients received conventional antihypertensive therapy. The primary outcome was the composite of a doubling of the serum creatinine level, end-stage renal disease, or death. Secondary end points included changes in the level of proteinuria and the rate of progression of renal disease.
Results
Of 102 patients in group 1, 22 (22 percent) reached the primary end point, as compared with 44 of 108 patients given benazepril in group 2 (41 percent) and 65 of 107 patients given placebo in group 2 (60 percent). As compared with placebo, benazepril was associated with a 43 percent reduction in the risk of the primary end point in group 2 (P=0.005). This benefit did not appear to be attributable to blood-pressure control. Benazepril therapy was associated with a 52 percent reduction in the level of proteinuria and a reduction of 23 percent in the rate of decline in renal function. The overall incidence of major adverse events in the benazepril and placebo subgroups of group 2 was similar.
Conclusions
Benazepril conferred substantial renal benefits in patients without diabetes who had advanced renal insufficiency. (ClinicalTrials.gov number, NCT00270426.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Kaplan–Meier Estimates of the Percentage of Patients Not Reaching the Primary Composite End Point of a Doubling of the Serum Creatinine Level, End-Stage Renal Disease, or Death.Article Activity
- Article
Angiotensin-converting–enzyme (ACE) inhibitors slow the progression of chronic kidney disease in the presence or absence of diabetes, particularly in patients with mild-to-moderate renal insufficiency, as reflected by a serum creatinine level of 1.5 to 3.0 mg per deciliter (133 to 265 μmol per liter).1-3 Data, however, have been limited to patients with serum creatinine levels of 3.0 mg per deciliter or less. Many physicians are reluctant to use ACE inhibitors in patients with advanced renal insufficiency because of concern that serum creatinine or potassium levels will rise.4,5 Many infer that the unique benefits of these drugs in patients with advanced renal failure might not be superior to those afforded by blood-pressure control alone.4 As a result, patients with advanced chronic kidney disease have not been included in prospective, large-scale clinical trials of ACE inhibitors.1,6 Consequently, the renal outcome and the risk–benefit profile of ACE inhibitors in this population remain poorly defined.
In China, the primary cause of end-stage renal disease is nondiabetic chronic kidney disease.7,8 In 1999, 41,000 registered patients were receiving dialysis, accounting for 5 percent of the total population requiring renal-replacement therapy.7 Thus, therapy that could delay the progression of chronic kidney disease to end-stage renal disease is an essential management goal. Our previous open-label study involving a small number of patients with advanced chronic renal disease, some with and some without diabetes, suggested that benazepril, a nonsulfhydryl-containing ACE inhibitor, may confer renal benefits.9 The present randomized, double-blind study was designed to determine whether benazepril could slow the progression of renal dysfunction in patients without diabetes who had advanced renal insufficiency.
Methods
Study Design
The study was conducted at the Nanfang Hospital Renal Division, a center of kidney disease care in southern China. The catchment area of the center includes eight cities near Guangzhou with a total population of 29.8 million as of 2000. The principal investigator and the steering committee designed the study and wrote the article. An adjudicating committee, whose members were unaware of patients' treatment assignments, reviewed the data to determine which patients had reached study end points; this committee also evaluated safety. The study protocol was approved by the Nanfang Ethics Committee, and all subjects provided written informed consent. A study period of three years was chosen on the basis of the results of previous trials involving patients with nondiabetic chronic kidney disease, which suggested that a three-year follow-up is adequate to assess efficacy.1,2
Patients
Between May 1999 and May 2001, we screened consecutive patients with chronic kidney disease who were 18 to 70 years of age. All the patients were Chinese. Eligible patients had not received ACE inhibitors or angiotensin II–receptor antagonists for at least six weeks before screening and met the following inclusion criteria: a serum creatinine level of 1.5 to 5.0 mg per deciliter (133 to 442 μmol per liter) and a creatinine clearance10 of 20 to 70 ml per minute per 1.73 m2, with variations of less than 30 percent in the three months before screening; nondiabetic renal disease (as established on the basis of their history and the results of serum biochemical tests and renal biopsy); and persistent proteinuria (defined by urinary protein excretion of more than 0.3 g per day for three or more months without evidence of urinary tract infection or overt heart failure [a New York Heart Association class of III or IV]). Exclusion criteria included an immediate need for dialysis; current treatment with corticosteroids, nonsteroidal antiinflammatory drugs, or immunosuppressive drugs; renovascular disease; myocardial infarction or cerebrovascular accident in the year preceding the trial; connective-tissue disease; and obstructive uropathy.
Treatment
Eligible patients were divided into two groups according to their serum creatinine levels: group 1 consisted of patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter, and group 2 consisted of patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (274 to 442 μmol per liter). All patients entered an eight-week run-in phase during which they received 10 mg of benazepril per day for four weeks under close observation, including weekly measurements of blood pressure, serum creatinine, and serum potassium. The dose of benazepril was increased to 10 mg twice daily for an additional four weeks if serum creatinine levels remained unchanged or increased less than 30 percent, serum potassium levels remained below 5.6 mmol per liter, and no adverse events were reported. Open-label antihypertensive agents (diuretics, calcium-channel antagonists, alpha- or beta-blockers, or some combination of these medications, excluding ACE inhibitors and angiotensin II–receptor antagonists) were added as necessary to achieve a systolic blood pressure of less than 130 mm Hg and a diastolic blood pressure of less than 80 mm Hg.
After the run-in phase, benazepril was discontinued for three weeks and alternative antihypertensive agents (as described above) were administered as necessary to maintain blood-pressure control. After three weeks, all patients in group 1 received 10 mg of benazepril twice daily. Because of the known renal protective effects of ACE inhibitors in patients with this stage of chronic kidney disease, the ethics committee decided that these patients should not receive placebo. Patients in group 2 were randomly assigned to receive either 10 mg of benazepril twice daily or placebo, along with conventional antihypertensive therapy as required. A computer-generated list, maintained by a party not involved in the conduct of the study, was used for randomization.
A physician who was unaware of the patients' treatment assignments examined each patient every two weeks during the first month and every three months thereafter. At each examination, blood pressure was measured while the patient was seated three to four hours after the administration of the study drug and laboratory measurements were performed to assess whether adverse events had occurred or end points had been reached.
All patients were advised to reduce their salt intake to approximately 5 to 7 g of sodium chloride per day, to eat 0.5 to 0.7 g of protein per kilogram of body weight per day, and to restrict their intake of foods rich in potassium. Dietary compliance was assessed by evaluating daily urinary urea and chloride excretion.
Outcome Measures
The primary efficacy measure was the time to the first event in the composite end point of a doubling of the serum creatinine level, end-stage renal disease, or death. A doubling of the serum creatinine level was defined as two serum creatinine values obtained at least four weeks apart that were twice the baseline value. End-stage renal disease was defined by the need for long-term dialysis or renal transplantation.
Secondary end points included changes in the rate of urinary protein excretion and the progression of renal disease, as assessed by the reciprocal of the serum creatinine level,11 creatinine clearance, and the glomerular filtration rate, as calculated with the use of the four-component Modification of Diet in Renal Disease equation incorporating age, race, sex, and serum creatinine level12-15: estimated glomerular filtration rate = 186 × (serum creatinine level [in milligrams per deciliter])−1.154 × (age [in years])−0.203. For women, the product of this equation was multiplied by a correction factor of 0.742.
Statistical Analysis
The sample size was estimated before the study with the use of nQuery Advisor software. Our preliminary study9 of the treatment of patients with advanced renal dysfunction showed that the two-year rate of the primary end point among patients who were not taking an ACE inhibitor was 60 percent. It was estimated that ACE-inhibitor treatment would reduce this rate to 40 percent. Thus, the enrollment of 100 patients per group would provide the study with a statistical power of 80 percent at a two-sided significance level of 0.05.
The primary and secondary end points were analyzed according to the intention-to-treat principle. A Cox regression model was used to determine the hazard ratio for the primary end point. The risk reduction was calculated as 100 percent × (1 − the hazard ratio). Event curves are based on Kaplan–Meier analysis, and significance was assessed by means of the log-rank test.
Changes in the level of urinary protein excretion, creatinine clearance, and blood pressure were analyzed by repeated-measures analysis of variance. To identify interactions between the treatment groups and blood pressure, we used proportional-hazards regression and the most recent measurement of mean arterial pressure as a time-varying covariate. The relationship between the reduction in proteinuria and the rate of the decline in renal function was analyzed by Pearson correlation. SPSS software for Windows (version 12.0) was used for analyses.
Results
We screened 468 patients, and 422 entered the run-in phase: 141 had a serum creatinine level of 1.5 to 3.0 mg per deciliter and were therefore in group 1, and 281 had a serum creatinine level of 3.1 to 5.0 mg per deciliter and were thus in group 2 (Figure 1Figure 1
Enrollment and Outcomes.). Before randomization, 94 patients were excluded: 72 patients had a dry cough (17 percent, 30 in group 1 and 42 in group 2), 9 had an acute increase in the serum creatinine level of more than 30 percent (2 percent, 3 in group 1 and 6 in group 2), 5 had an increase in the serum potassium level to more than 5.6 mmol per liter (1 percent, 1 in group 1 and 4 in group 2), and 8 had a rate of adherence to medication of less than 80 percent (2 percent, 3 in group 1 and 5 in group 2). There were no significant differences in these events between the two groups.All 104 patients in group 1 received 20 mg of benazepril per day, whereas in group 2, 112 patients were randomly assigned to receive 20 mg of benazepril per day and 112 were assigned to receive placebo. The baseline characteristics of the patients were similar in the two subgroups of group 2 (Table 1Table 1
Baseline Characteristics of the Patients with Chronic Kidney Disease.). The average age and the distribution of the primary causes of renal dysfunction in the various groups were similar to those reported in the registry of the Chinese Society of Nephrology.7 The mean length of follow-up was 3.4 years (range, 2 to 5). Eleven patients were lost to follow-up (2 in group 1, 5 assigned to benazepril in group 2, and 4 assigned to placebo in group 2), leaving 102 patients in group 1 and 215 patients in group 2 (107 assigned to benazepril and 108 assigned to placebo) who could be included in the efficacy analysis.Primary Outcomes
In group 2, 44 patients assigned to benazepril reached the primary end point, as compared with 65 patients assigned to placebo (41 percent vs. 60 percent, P=0.004) (Figure 2Figure 2
Kaplan–Meier Estimates of the Percentage of Patients Not Reaching the Primary Composite End Point of a Doubling of the Serum Creatinine Level, End-Stage Renal Disease, or Death.). However, renal outcome, as measured by the number of patients who reached the primary end point, was worse among patients assigned to benazepril in group 2 than among patients in group 1, even though all patients received the same dose of benazepril (P=0.003) (Figure 2).In group 2, treatment with benazepril, as compared with placebo, resulted in a 43 percent overall reduction in the risk of the primary end point (P=0.005). The decrease in the risk (hazard rate, 40 percent) remained significant after adjustment for differences in the mean arterial pressure (P=0.009). The intention-to-treat analyses of the individual components of the primary end point indicated that the risk of a doubling of the serum creatinine level was 51 percent lower among patients who received benazepril than among those given placebo (P=0.02). Benazepril also reduced the risk of end-stage renal disease by 40 percent (P=0.02).
Blood Pressure
Classes of conventional antihypertensive drugs used before and during the study are listed in Table 2Table 2
Use of Conventional Antihypertensive Medications at Baseline and during Study Treatment.. Blood pressure declined progressively during the study (Figure 3AFigure 3
Changes in Blood Pressure (Panel A), the Level of Proteinuria (Panel B), and Creatinine Clearance (Panel C) during Follow-up.). The decline in blood pressure was similar in the two groups (P=0.26) and in the two subgroups of group 2 (P=0.18).Secondary Outcomes
In group 2, there was a significantly greater reduction in the level of proteinuria among patients assigned to benazepril than among those assigned to placebo (52 percent vs. 20 percent, P<0.001) (Figure 3B). Urinary protein excretion was also decreased in group 1, with an average reduction of 49 percent (P=0.57 for the comparison with patients assigned to benazepril in group 2) (Figure 3B). Benazepril also reduced the rate of decline in renal function by 23 percent in group 2, as assessed by the reciprocal of the serum creatinine level (median slope, –0.09 dl per milligram per year among those assigned to benazepril, as compared with –0.11 dl per milligram per year among those assigned to placebo; P=0.02).
Likewise, benazepril was associated with a 24 percent reduction in the estimated decline in the glomerular filtration rate in group 2: the median rate of decline was 6.8 ml per minute per 1.73 m2 per year among the patients assigned to benazepril, as compared with 8.8 ml per minute per 1.73 m2 per year among the patients assigned to placebo (P=0.006). There was no significant difference between the two benazepril groups in the rate of decline in the estimated glomerular filtration rate (P=0.23) or creatinine clearance (P=0.19) (Figure 3C). However, there was a significant correlation between the extent of the reduction in proteinuria and the rate of decline in both the estimated glomerular filtration rate (P=0.03) and creatinine clearance (P=0.03) in patients with proteinuria of at least 1 g per day at baseline.
Safety
One patient assigned to benazepril in group 2 died of pneumonia. The last measurement obtained in this patient showed good blood-pressure control (120/80 mm Hg) and a normal serum potassium level. There were no significant differences in the number of nonfatal cardiovascular events between the two groups or between the two subgroups in group 2 (Table 3Table 3
Adverse Events after Randomization.). The incidence of other adverse events was also similar in the two groups and in the two subgroups of group 2. Hyperkalemia (defined as a serum potassium level of at least 6.0 mmol per liter) occurred in 11 patients (5 percent) in group 2. Of these 11 patients, 8 were successfully treated with dietary modifications, concomitant diuretic therapy, and optimized acid–base balance. The remaining three patients withdrew from the study. Follow-up serum potassium levels in group 2 were higher among patients receiving benazepril than among those receiving placebo (P=0.001), but the differences never exceeded 0.5 mmol per liter. In group 2, the proportion of patients receiving recombinant human erythropoietin, the mean dose of recombinant human erythropoietin, and hemoglobin levels were similar in the two subgroups at baseline and during the study (data not shown).Discussion
Our findings indicate that benazepril, along with conventional antihypertensive treatment, as needed, confers renal protection in patients without diabetes who have advanced renal insufficiency. Benazepril therapy reduced the risk of the primary end point by 43 percent among patients quite close to end-stage renal disease during an average follow-up of 3.4 years. The difference between the slopes of the reciprocal of the serum creatinine level and the slower decline in creatinine clearance and the glomerular filtration rate with benazepril therapy provide further evidence of the renal protection afforded by this ACE inhibitor. Thus, the primary analysis of this controlled trial provides evidence that treatment with the ACE inhibitor benazepril is beneficial in patients with stage 4 chronic kidney disease (defined by a glomerular filtration rate of 15 to 29 ml per minute per 1.73 m2). Although a previous secondary analysis suggested a benefit of ACE inhibitors among patients with severe renal dysfunction,16 evidence from a randomized, controlled trial is necessary to confirm the efficacy and tolerability of these agents in this patient population. Since current information indicates that 85 percent of patients with stage 4 chronic kidney disease are not offered such renal protective treatment,16 our results may have important implications for the development of new therapeutic guidelines.
Consistent with previous findings,16,17 our data suggest that the response to ACE inhibitors was independent of the baseline glomerular filtration rate. The rate of decrease in the glomerular filtration rate appeared to be higher among patients in group 2 than among those in group 1 and was moderately reduced by ACE inhibitors. This observation is consistent with the report that enalapril slowed the progression of advanced chronic kidney disease in patients without diabetes.18 The higher proportion of patients reaching the primary end point in group 2 might be explained by the fact that the ACE-inhibitor–associated reduction in risk is time-dependent18,19 and that patients with advanced chronic kidney disease had been treated for a shorter period than those with more preserved renal function. Thus, to achieve maximal renal protection, treatment with ACE inhibitors should arguably be initiated at earlier stages of chronic kidney disease.
Our study was also designed to determine whether the renal protective effect of benazepril in patients with advanced chronic kidney disease is dependent on its antihypertensive action. Blood pressure and the use of conventional antihypertensive drugs were similar at baseline and during treatment in both subgroups of group 2. Furthermore, the reduction in the risk of the primary end point changed little after correction for blood pressure, suggesting that the renal protection conferred by benazepril is not dependent on blood pressure when the drug is used as part of combination antihypertensive therapy.
The most striking difference between the patients who received benazepril and the patients who received placebo in group 2 was the change in urinary protein excretion. Benazepril greatly reduced urinary protein excretion in patients with advanced chronic kidney disease. This observation, as well as the close correlation between the extent of the reduction in proteinuria and the rate of decline in renal function, provides further support for, but does not prove, the hypothesis that proteinuria has a causal role in the progression of renal dysfunction.17,20
Patients with stage 4 chronic kidney disease are particularly vulnerable to the effects of ACE inhibitors on the glomerular filtration rate and potassium excretion.21,22 For safety's sake, as well as because of the higher incidence of dry cough among Chinese patients taking ACE inhibitors than among other ethnic groups receiving these drugs,23 we treated all eligible patients with benazepril and observed them closely during the run-in period. Dry cough and an acute increase in the serum creatinine level occurred mostly within the first two months after the initiation of benazepril therapy, but there were no significant differences in the incidence of these adverse events between patients in group 1 and those in group 2. Benazepril-associated cough was reported in 17 percent of patients during the run-in period, though as compared with patients in other studies, fewer of those with cough reported that this was an intolerable side effect.23 Nine patients had an increase in the serum creatinine level that exceeded 30 percent during the run-in phase, and five patients were evaluated for renal-artery stenosis (two in group 1 and three in group 2).
In the cohort with advanced renal dysfunction, the tolerability of benazepril and placebo was similar, as evidenced by the similar incidence of major adverse events in the two subgroups. As predicted, a nonsignificant trend toward a higher frequency of hyperkalemia was observed in group 2 as compared with group 1. However, the incidence of hyperkalemia was similar among patients who received benazepril and those who received placebo in group 2, and benazepril therapy resulted in an average increase in the serum potassium level that never exceeded 0.5 mmol per liter. Furthermore, benazepril had no significant effects on patients' hemoglobin levels or the dose of recombinant human erythropoietin. These data suggest that the addition of benazepril to a conventional regimen of antihypertensive therapy is acceptable, even in patients with serum creatinine levels exceeding 3.0 mg per deciliter. Nonetheless, blood pressure, renal function, and serum potassium levels should be monitored regularly in patients with advanced chronic kidney disease, especially during the first two months of ACE-inhibitor therapy and as renal function changes.
In summary, benazepril therapy was associated with a significant improvement in renal outcome and surpassed that attributable to blood-pressure control in patients without diabetes who had advanced renal dysfunction.
Supported by a National Nature and Sciences Grant for Major Projects (30330300) and a People's Liberation Army Grant for Major Clinical Research (to Dr. Hou) and in part by Novartis.
No potential conflict of interest relevant to this article was reported.
Source Information
From the Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Address reprint requests to Dr. Hou at the Renal Division, Nanfang Hospital, 1838 N. Guangzhou Ave., Guangzhou 510515, China, or at ffhou@public.guangzhou.gd.cn.
Appendix
The following persons participated in the study: Principal Investigator: F.F. Hou; Steering Panel: F.F. Hou, X. Zhang, G.H. Zhang; End-Point and Safety Monitoring Panel: M. Liang, D. Xie, W.R. Zhang; Primary Investigators: Z.R. Liu, J.P. Jiang, G.B. Wang, H. Ren, H.F. Liu, X.B. Yang, Z.J. Guo, H.Y. Li, X.Y. Shi, H.X. Niu.
- References
References
1
Maschio G ,Alberti D ,Janin G , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945
Full Text | Web of Science | Medline2
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)
CrossRef | Web of Science | Medline3
Ruggenenti P ,Perna A ,Benini R ,Remuzzi G . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998;9:2096-2101
Web of Science | Medline4
Bakris GL ,Weir MR . Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-693
CrossRef | Web of Science | Medline5
Moser M . Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. J Am Coll Cardiol 1997;29:1414-1421
CrossRef | Web of Science | Medline6
Lewis EJ ,Hunsicker LG ,Bain RP ,Rohde RD . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462[Erratum, N Engl J Med 1993;330:152.]
Full Text | Web of Science | Medline7
Dialysis and Transplantation Registration Group, Chinese Society of Nephrology 8
Hou FF ,Ma ZG ,Mei CL , et al. Cardiovascular disease in Chinese chronic renal insufficiency patients -- epidemiology survey. Zhonghua Yi Xue Za Zhi 2005;85:458-463
Medline9
Zhang GH ,Hou FF ,Zhang X ,Liu QF . Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L? Zhonghua Nei Ke Za Zhi 2005;44:592-596
Medline10
Levey AS. Clinical evaluation of renal function. In: Greenberg A, ed. Primer on kidney diseases. 2nd ed. San Diego, Calif.: Academic Press, 1998:20-6.
11
Mitch WE ,Walser M ,Buffington GA ,Lemann J Jr . A simple method of estimating progression of chronic renal failure. Lancet 1976;2:1326-1328
CrossRef | Web of Science | Medline12
Levey AS ,Greene T ,Kusek JW ,Beck GJ . A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:155A-155A abstract.13
Levey AS ,Bosch JP ,Lewis JB ,Greene T ,Rogers N ,Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
Web of Science | Medline14
Coresh J ,Astor BC ,McQuillan G , et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002;39:920-929
CrossRef | Web of Science | Medline15
Zuo L ,Ma YC ,Zhou YH ,Wang M ,Xu GB ,Wang HY . Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis 2005;45:463-472
CrossRef | Web of Science | Medline16
Ruggenenti P, Perna A, Remuzzi G, Gruppo Italiano di Studi Epidemiologici in Nefrologia
Web of Science | Medline17
Ruggenenti P ,Perna A ,Mosconi L ,Pisoni R ,Remuzzi G . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 1998;53:1209-1216
CrossRef | Web of Science | Medline18
Ihle BU ,Whitworth JA ,Shahinfar S ,Cnaan A ,Kincaid-Smith PS ,Becker GJ . Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996;27:489-495
CrossRef | Web of Science | Medline19
Ruggenenti P ,Perna A ,Benini R , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol 1999;10:997-1006
Web of Science | Medline20
Peterson JC ,Adler S ,Burkart JM , et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-762
Web of Science | Medline21
Reams GP ,Bauer JH . Effect of lisinopril monotherapy on renal hemodynamics. Am J Kidney Dis 1988;11:499-507
Web of Science | Medline22
Reardon LC ,Macpherson DS . Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med 1998;158:26-32
CrossRef | Web of Science | Medline23
Tomlinson B ,Woo J ,Thomas GN ,Chau YM ,Critchley JA . Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult Chinese patients with hypertension. Clin Ther 2004;26:1292-1304
CrossRef | Web of Science | Medline
- Citing Articles (117)
Citing Articles
1
Ali Ahmed, Gregg C. Fonarow, Yan Zhang, Paul W. Sanders, Richard M. Allman, Donna K. Arnett, Margaret A. Feller, Thomas E. Love, Inmaculada B. Aban, Raynald Levesque, O. James Ekundayo, Louis J. Dell'Italia, George L. Bakris, Michael W. Rich. (2012) Renin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease. The American Journal of Medicine
CrossRef2
Ali A. Valika, Mihai Gheorghiade. (2012) Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature. Heart Failure Reviews
CrossRef3
C. Barrett Bowling, Paul W. Sanders, Richard M. Allman, William J. Rogers, Kanan Patel, Inmaculada B. Aban, Michael W. Rich, Bertram Pitt, Michel White, George C. Bakris, Gregg C. Fonarow, Ali Ahmed. (2012) Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: Insights from the SOLVD Treatment trial. International Journal of Cardiology
CrossRef4
Colleen Flynn, George L. Bakris. (2011) Blood Pressure Targets for Patients with Diabetes or Kidney Disease. Current Hypertension Reports 13:6, 452-455
CrossRef5
Yong-jun Wang, Li-qun He, Wei Sun, Ying Lu, Xiao-qin Wang, Pei-qing Zhang, Lian-bo Wei, Shi-li Cao, Ni-zhi Yang, Hong-zhen Ma, Jing Gao, Ping Li, Xiao-juan Tao, Fa-Huan Yuan, Jing Li, Chen Yao, Xusheng Liu. (2011) Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: A multicenter double-blinded randomized controlled trial. Journal of Ethnopharmacology
CrossRef6
Thierry Krummel, Anne-Laure Faller, Dorothée Bazin, Thierry Hannedouche. (2011) Les promesses de la néphroprotection à l’épreuve des faits. La Presse Médicale 40:11, 1037-1042
CrossRef7
Pawana Sharma, Rachel C Blackburn, Claire L Parke, Keith McCullough, Angharad Marks, Corri Black, Corri Black. 2011. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. .
CrossRef8
Khaled Abdel-Kader, Gary S. Fischer, Jie Li, Charity G. Moore, Rachel Hess, Mark L. Unruh. (2011) Automated Clinical Reminders for Primary Care Providers in the Care of CKD: A Small Cluster-Randomized Controlled Trial. American Journal of Kidney Diseases
CrossRef9
Fumihiko Koiwa, Daisuke Komukai, Makoto Hirose, Ashio Yoshimura, Ryoichi Ando, Toshifumi Sakaguchi, Yasuhiro Komatsu, Toshio Shinoda, Daijo Inaguma, Nobuhiko Joki, Hidemi Nishida, Masato Ikeda, Takashi Shigematsu. (2011) Influence of renin–angiotensin system on serum parathyroid hormone levels in uremic patients. Clinical and Experimental Nephrology
CrossRef10
Joseph L. Izzo Jr, Matthew R. Weir. (2011) Angiotensin-Converting Enzyme Inhibitors. The Journal of Clinical Hypertension 13:9, 667-675
CrossRef11
Philippe Gatault, Azmi Al-Najjar, Christelle Barbet, Mélanie Roland, Inass Laouad, Matthias Buchler, Jean-Frédéric Marlière, Pierre Emmanuel Métais, Alice Clément, Hubert Nivet, Yvon Lebranchu, Jean-Michel Halimi. (2011) Doubling of Serum Creatinine in Clinical Trials, Cost-Effectiveness Studies, and Individual Patients: Adequate Use in Renal Transplantation. Transplantation1
CrossRef12
F. Bonnet, E. Gauthier, H. Gin, S. Hadjadj, J.-M. Halimi, T. Hannedouche, V. Rigalleau, D. Romand, R. Roussel, P. Zaoui. (2011) Expert consensus on management of diabetic patients with impairment of renal function. Diabetes & Metabolism 37, S1-S25
CrossRef13
A. Maione, S. D. Navaneethan, G. Graziano, R. Mitchell, D. Johnson, J. F. E. Mann, P. Gao, J. C. Craig, G. Tognoni, V. Perkovic, A. Nicolucci, S. De Cosmo, A. Sasso, O. Lamacchia, M. Cignarelli, V. Maria Manfreda, G. Gentile, G. F. M. Strippoli. (2011) Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrology Dialysis Transplantation 26:9, 2827-2847
CrossRef14
Sai H. S. Boddu, Deep Kwatra, Ashim K. Mitra. 2011. Prodrug Strategies to Enhance Oral Drug Absorption. , 355-369.
CrossRef15
Devasmita Choudhury, Moshe Levi. (2011) Kidney aging—inevitable or preventable?. Nature Reviews Nephrology
CrossRef16
Bum-Yeol Hwang, Minho Cha, Hyung-Yeon Park, Byung-Gee Kim. (2011) Aminotransferase-catalyzed asymmetric synthesis of benazepril intermediate. Biotechnology and Bioprocess Engineering 16:4, 625-630
CrossRef17
Hiddo J. Lambers Heerspink. (2011) Therapeutic Approaches in Lowering Albuminuria: Travels Along the Renin-Angiotensin-Aldosterone-System Pathway. Advances in Chronic Kidney Disease 18:4, 290-299
CrossRef18
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley, Robert A. Harrington, Eric R. Bates, Deepak L. Bhatt, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, John D. Fisher, Timothy J. Gardner, Federico Gentile, Michael F. Gilson, Mark A. Hlatky, Alice K. Jacobs, Sanjay Kaul, David J. Moliterno, Debabrata Mukherjee, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American Society of Hypertension 5:4, 259-352
CrossRef19
Elke Wühl, Franz Schaefer. (2011) Managing kidney disease with blood-pressure control. Nature Reviews Nephrology 7:8, 434-444
CrossRef20
Tomasz Stompór, Maria Napora, Artur Olszewski. (2011) Renoprotective effects of benazepril: current perspective. Expert Review of Cardiovascular Therapy 9:6, 663-673
CrossRef21
Chih-Kang Chiang, Meei-Ling Sheu, Yi-Wei Lin, Cheng-Tien Wu, Chin-Ching Yang, Min-Wei Chen, Kuan-Yu Hung, Kuan-Dun Wu, Shing-Hwa Liu. (2011) Honokiol ameliorates renal fibrosis by inhibiting extracellular matrix and pro-inflammatory factors in vivo and in vitro. British Journal of Pharmacology 163:3, 586-597
CrossRef22
Louis Kuritzky, Robert Toto, Peter Van Buren. (2011) Identification and Management of Albuminuria in the Primary Care Setting. The Journal of Clinical Hypertension 13:6, 438-449
CrossRef23
C. Gómez-Alamillo, M. Gago Fraile, G. Fernández-Fresnedo, M. Arias Rodríguez. (2011) Nefropatía hipertensiva. Medicine - Programa de Formación Médica Continuada Acreditado 10:81, 5474-5483
CrossRef24
Takahito Moriyama, Yuki Tsuruta, Chiari Kojima, Mitsuyo Itabashi, Hidekazu Sugiura, Takashi Takei, Tetsuya Ogawa, Keiko Uchida, Ken Tsuchiya, Kosaku Nitta. (2011) Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. International Urology and Nephrology
CrossRef25
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American College of Cardiology 57:20, 2037-2114
CrossRef26
Charles Christian Adarkwah, Afschin Gandjour. (2011) Cost–effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease. Expert Review of Pharmacoeconomics & Outcomes Research 11:2, 215-223
CrossRef27
N. Stoycheff, K. Pandya, A. Okparavero, A. Schiff, A. S. Levey, T. Greene, L. A. Stevens. (2011) Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrology Dialysis Transplantation 26:3, 848-857
CrossRef28
Noriko Takeuchi, Emi Takenoshita, Fumino Kato, Tomoko Terajima, Makoto Ogawa, Satoshi Suzuki, Takayuki Fujii, Eriko Kobayashi, Tomoya Sakurada, Nobunori Satoh, Shiro Ueda. (2011) Doubling of serum creatinine: is it appropriate as the endpoint for CKD? Proposal of a new surrogate endpoint based on the reciprocal of serum creatinine. Clinical and Experimental Nephrology 15:1, 100-107
CrossRef29
Valentina Kon, MacRae F. Linton, Sergio Fazio. (2011) Atherosclerosis in chronic kidney disease: the role of macrophages. Nature Reviews Nephrology 7:1, 45-54
CrossRef30
Marsha A. Raebel. (2011) Hyperkalemia Associated with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Cardiovascular Therapeuticsno-no
CrossRef31
Anderson Roman Gonçalves, Arif Khwaja, Aimune K. Ahmed, Mohsen El Kossi, Meguid El Nahas. (2011) Stopping Renin-Angiotensin System Inhibitors in Chronic Kidney Disease: Predictors of Response. Nephron Clinical Practice 119:4, c348-c354
CrossRef32
Mark S. MacGregor, Maarten W. Taal. (2011) Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. Nephron Clinical Practice 118:s1, c71-c100
CrossRef33
Khaled Abdel-Kader, Gary S Fischer, James R Johnston, Chen Gu, Charity G Moore, Mark L Unruh. (2011) Characterizing pre-dialysis care in the era of eGFR reporting: a cohort study. BMC Nephrology 12:1, 12
CrossRef34
Vivencio Barrios, Carlos Escobar. (2010) Antihypertensive and organ-protective effects of benazepril. Expert Review of Cardiovascular Therapy 8:12, 1653-1671
CrossRef35
A. K. Ahmed, N. S. Kamath, M. El Kossi, A. M. El Nahas. (2010) The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrology Dialysis Transplantation 25:12, 3977-3982
CrossRef36
Timm Bauer, Anselm K. Gitt, Claus Jünger, Ralf Zahn, Oliver Koeth, Frank Towae, Arne K. Schwarz, Kurt Bestehorn, Jochen Senges, Uwe Zeymer. (2010) Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. European Journal of Cardiovascular Prevention & Rehabilitation 17:5, 576-581
CrossRef37
Kevin V. Lemley. (2010) When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes. Pediatric Nephrology 25:10, 2021-2034
CrossRef38
Michael R. Lattanzio, Matthew R. Weir. (2010) Does Blockade of the Renin-Angiotensin-Aldosterone System Slow Progression of All Forms of Kidney Disease?. Current Hypertension Reports 12:5, 369-377
CrossRef39
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2010) Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes. American Journal of Kidney Diseases 56:4, 759-773
CrossRef40
P. A. Swift, P. A. Andrews. (2010) Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required. International Journal of Clinical Practice 64:10, 1331-1333
CrossRef41
V. L. M. Esnault, A. Ekhlas, J.-M. Nguyen, O. Moranne. (2010) Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration. Nephrology Dialysis Transplantation 25:7, 2218-2224
CrossRef42
Kiyotsugu Omae, Tetsuya Ogawa, Kosaku Nitta. (2010) Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease. Heart and Vessels 25:3, 203-208
CrossRef43
David Benavente, Colin D. Chue, Charles J. Ferro. (2010) THE IMPORTANCE OF RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH CARDIO-RENAL DISEASE. Journal of Renal Care 36, 97-105
CrossRef44
Daisuke Yamamoto, Shinji Takai, Ichiro Hirahara, Eiji Kusano. (2010) Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clinica Chimica Acta 411:9-10, 762-764
CrossRef45
Matthew T James, Brenda R Hemmelgarn, Marcello Tonelli. (2010) Early recognition and prevention of chronic kidney disease. The Lancet 375:9722, 1296-1309
CrossRef46
George L Bakris, Pantelis A Sarafidis, Matthew R Weir, Björn Dahlöf, Bertram Pitt, Kenneth Jamerson, Eric J Velazquez, Linda Staikos-Byrne, Roxzana Y Kelly, Victor Shi, Yann-Tong Chiang, Michael A Weber. (2010) Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 375:9721, 1173-1181
CrossRef47
Abboud, Hanna, Henrich, William L., . (2010) Stage IV Chronic Kidney Disease. New England Journal of Medicine 362:1, 56-65
Full Text48
Xiaoyue Tan, Weichun He, Youhua Liu. (2009) Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney International 76:12, 1248-1257
CrossRef49
Ai-Hua Zhang, Paul Tam, Denise LeBlanc, Hui Zhong, Christopher T. Chan, Joanne M. Bargman, Dimitrios G. Oreopoulos. (2009) Natural history of CKD stage 4 and 5 patients following referral to renal management clinic. International Urology and Nephrology 41:4, 977-982
CrossRef50
Rigas G. Kalaitzidis, George L. Bakris. (2009) The current state of RAAS blockade in the treatment of hypertension and proteinuria. Current Cardiology Reports 11:6, 436-442
CrossRef51
The ESCAPE Trial Group. (2009) Strict Blood-Pressure Control and Progression of Renal Failure in Children. New England Journal of Medicine 361:17, 1639-1650
Full Text52
BOON W TEO, ZHI Y NG, JIALIANG LI, SHARON SAW, SUNIL SETHI, EVAN JC LEE. (2009) The choice of estimating equations for glomerular filtration rate significantly affects the prevalence of chronic kidney disease in a multi-ethnic population during health screening. Nephrology 14:6, 588-596
CrossRef53
J. Díez. (2009) Enfoque nefrológico del bloqueo del sistema renina-angiotensina para el tratamiento de la hipertensión. Revista Clínica Española 209, 3-8
CrossRef54
Rigas G Kalaitzidis, George L Bakris. (2009) Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?. Current Opinion in Nephrology and Hypertension 18:5, 386-391
CrossRef55
K.F. Hilgers. (2009) Das Renin-Angiotensin-System. Der Nephrologe 4:4, 351-361
CrossRef56
Rigas Kalaitzidis, George L Bakris. (2009) Effects of angiotensin II receptor blockers on diabetic nephropathy. Journal of Hypertension 27:Suppl 5, S15-S21
CrossRef57
M. Evans, C. M. Fored, R. Bellocco, G. Fitzmaurice, J. P. Fryzek, J. K. McLaughlin, O. Nyren, C.-G. Elinder. (2009) Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrology Dialysis Transplantation 24:6, 1908-1918
CrossRef58
Takao Saruta, Koichi Hayashi, Toshio Ogihara, Kazuwa Nakao, Tsuguya Fukui, Kohshiro Fukiyama. (2009) Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study. Hypertension Research 32:6, 505-512
CrossRef59
R. Marín, M. Gorostidi, R. Álvarez-Navascués, S. García-Melendreras. (2009) Tratamiento de la hipertensión arterial en pacientes con enfermedad renal crónica. Evidencias e implicaciones. Medicina Clínica 132, 20-26
CrossRef60
K.H. Rahn. (2009) Leitliniengerechte Differenzialtherapie der Hypertonie. Der Internist 50:4, 433-441
CrossRef61
Donah Zachariah, Philip A. Kalra, Paul R. Kalra. (2009) OPTIMAL MANAGEMENT OF CHRONIC HEART FAILURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Journal of Renal Care 35:1, 2-10
CrossRef62
Minmin Zhang, Jing Chen, Shaojun Liu, Li You, Shanyan Lin, Yong Gu. (2009) The Role of Na + -H + Exchanger Isoform 1 in Aldosterone-Induced Glomerulosclerosis in Vivo. Renal Failure 31:8, 726-735
CrossRef63
Jicheng Lv, Hong Zhang, Yuqing Chen, Guangtao Li, Lei Jiang, Ajay K. Singh, Haiyan Wang. (2009) Combination Therapy of Prednisone and ACE Inhibitor Versus ACE-Inhibitor Therapy Alone in Patients With IgA Nephropathy: A Randomized Controlled Trial. American Journal of Kidney Diseases 53:1, 26-32
CrossRef64
Kostas C. Siamopoulos, Rigas G. Kalaitzidis. (2008) Inhibition of the renin–angiotensin system and chronic kidney disease. International Urology and Nephrology 40:4, 1015-1025
CrossRef65
Michael J Ryan, Katherine R Tuttle. (2008) Elevations in serum creatinine with RAAS blockade: why isnʼt it a sign of kidney injury?. Current Opinion in Internal Medicine 7:6, 599-605
CrossRef66
Karen A. Griffin, Anil K. Bidani. (2008) Potential risks of calcium channel blockers in chronic kidney disease. Current Cardiology Reports 10:6, 448-455
CrossRef67
Natasha J McIntyre, Maarten W Taal. (2008) How to measure proteinuria?. Current Opinion in Nephrology and Hypertension 17:6, 600-603
CrossRef68
W. Fang, D. G. Oreopoulos, J. M. Bargman. (2008) Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrology Dialysis Transplantation 23:11, 3704-3710
CrossRef69
N. Thilly, S. Boini, M. Kessler, S. Briancon, L. Frimat. (2008) Management and control of hypertension and proteinuria in patients with advanced chronic kidney disease under nephrologist care or not: data from the AVENIR study (AVantagE de la Nephroprotection dans l'Insuffisance Renale). Nephrology Dialysis Transplantation 24:3, 934-939
CrossRef70
Biff F. Palmer. (2008) Hypertension management in patients with chronic kidney disease. Current Hypertension Reports 10:5, 367-373
CrossRef71
SUPRIYA MADDIRALA, AKRAM KHAN, ANDREA VINCENT, KAI LAU. (2008) Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Serum Potassium Levels and Renal Function in Ambulatory Outpatients: Risk Factors Analysis. The American Journal of the Medical Sciences 336:4, 330-335
CrossRef72
Domenic A. Sica. (2008) Management of Hypertension in the Outpatient Setting. Primary Care: Clinics in Office Practice 35:3, 451-473
CrossRef73
Michael J Ryan, Katherine R Tuttle. (2008) Elevations in serum creatinine with RAAS blockade: why isnʼt it a sign of kidney injury?. Current Opinion in Nephrology and Hypertension 17:5, 443-449
CrossRef74
Domenico Scrutinio, Pantaleo Giannuzzi. (2008) Comorbidity in patients undergoing coronary artery bypass graft surgery: impact on outcome and implications for cardiac rehabilitation. European Journal of Cardiovascular Prevention & Rehabilitation 15:4, 379-385
CrossRef75
Yoshifuru Tamura, Masahiro Kosuga, Masahiro Yamashita, Satoru Tomioka, Michiko Sasaki, Tomoyuki Hikita, Hideaki Nakajima, Kenichiro Kojima, Shunya Uchida. (2008) Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4–5 chronic kidney disease. Clinical and Experimental Nephrology 12:4, 256-263
CrossRef76
Katharina Hohenstein, Bruno Watschinger. (2008) Hypertonie und Niere. Wiener Medizinische Wochenschrift 158:13-14, 359-364
CrossRef77
Nathalie Thilly, Sahar Bayat, François Alla, Michèle Kessler, Serge Briançon, Luc Frimat. (2008) Determinants and patterns of renin-angiotensin system inhibitors’ prescription in the first year following kidney transplantation. Clinical Transplantation 22:4, 439-446
CrossRef78
Samina Khan, Chester A. Amedia. (2008) Economic burden of chronic kidney disease. Journal of Evaluation in Clinical Practice 14:3, 422-434
CrossRef79
R. Garrick. (2008) Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency. Yearbook of Medicine 2008, 233-234
CrossRef80
Yuansheng Xie, Xiangmei Chen. (2008) Epidemiology, Major Outcomes, Risk Factors, Prevention and Management of Chronic Kidney Disease in China. American Journal of Nephrology 28:1, 1-7
CrossRef81
Sang-Hee Lee, Young-Jo Kim, Woong Kim, Jong-Seon Park, Dong-Gu Shin, Seung-Ho Hur, Chong-Jin Kim, Myeong-Chan Cho, Shung-Chull Chae, Myung-Ho Jeong, Taek-Jong Hong, Doo-Il Kim, Kee-Sik Kim, Korean Acute Myocardial Infarction. (2008) Clinical Outcomes and Therapeutic Strategy in Patients With Acute Myocardial Infarction According to Renal Function. Circulation Journal 72:9, 1410-1418
CrossRef82
Maarten W. Taal. 2008. Prevention of Progressive Renal Failure. , 699-714.
CrossRef83
Sheldon Hirsch. (2007) Prerenal Success in Chronic Kidney Disease. The American Journal of Medicine 120:9, 754-759
CrossRef84
Alan K. Berger, Sue Duval, Connie Manske, Gabriela Vazquez, Cheryl Barber, Leslie Miller, Russell V. Luepker. (2007) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. American Heart Journal 153:6, 1064-1073
CrossRef85
TOSHIHIKO ISHIMITSU, AKIRA AKASHIBA, TOMOKO KAMEDA, TOSHIAKI TAKAHASHI, SATOSHI OHTA, MASAYOSHI YOSHII, JUNICHI MINAMI, HIDEHIKO ONO, ATSUSHI NUMABE, HIROAKI MATSUOKA. (2007) Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease. Nephrology 12:3, 294-298
CrossRef86
Laura M. Tanner, Kirsti Näntö-Salonen, Harri Niinikoski, Timo Jahnukainen, Päivi Keskinen, Heikki Saha, Kristiina Kananen, Antero Helanterä, Martti Metso, Marjatta Linnanvuo, Kirsi Huoponen, Olli Simell. (2007) Nephropathy Advancing to End-Stage Renal Disease: A Novel Complication of Lysinuric Protein Intolerance. The Journal of Pediatrics 150:6, 631-634.e1
CrossRef87
Christina Wyatt, Vinaya Konduri, John Eng, Rajeev Rohatgi. (2007) Reporting of Estimated GFR in the Primary Care Clinic. American Journal of Kidney Diseases 49:5, 634-641
CrossRef88
Heath E. Saltzman, Kumar Sharma, Paul J. Mather, Sharon Rubin, Suzanne Adams, David Joshua Whellan. (2007) Renal dysfunction in heart failure patients: what is the evidence?. Heart Failure Reviews 12:1, 37-47
CrossRef89
Roland E Schmieder, Karl F Hilgers, Markus P Schlaich, Bernhard MW Schmidt. (2007) Renin-angiotensin system and cardiovascular risk. The Lancet 369:9568, 1208-1219
CrossRef90
Sheldon Tobe, Kalina Kawecka-Jaszcz, Faiez Zannad, George Vetrovec, Rajiv Patni, Harry Shi. (2007) Amlodipine Added to Quinapril vs Quinapril Alone for the Treatment of Hypertension in Diabetes: The Amlodipine in Diabetes (ANDI) Trial. The Journal of Clinical Hypertension 9:2, 120-127
CrossRef91
P. Stiefelhagen. (2007) Internisten-Update 2006. Der Internist 48:2, 213-216
CrossRef92
Frederick A. Masoudi, Silvio E. Inzucchi. (2007) Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy. The American Journal of Cardiology 99:4, 113-132
CrossRef93
W.J. Elliott. (2007) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Yearbook of Cardiology 2007, 96-99
CrossRef94
W.J. Elliott. (2007) Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency. Yearbook of Cardiology 2007, 92-94
CrossRef95
R. Garrick. (2007) Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency. Yearbook of Medicine 2007, 200-201
CrossRef96
Andres Serrano, Jie Huang, Cybele Ghossein, Laura Nishi, Anupama Gangavathi, Vijayachitra Madhan, Paramesh Ramadugu, Shubhada N. Ahya, James Paparello, Neenoo Khosla, William Schlueter, Daniel Batlle. (2007) Stabilization of Glomerular Filtration Rate in Advanced Chronic Kidney Disease: A Two-Year Follow-up of a Cohort of Chronic Kidney Disease Patients Stages 4 and 5. Advances in Chronic Kidney Disease 14:1, 105-112
CrossRef97
Pantelis A. Sarafidis, Nitin Khosla, George L. Bakris. (2007) Antihypertensive Therapy in the Presence of Proteinuria. American Journal of Kidney Diseases 49:1, 12-26
CrossRef98
Sheldon Hirsch. (2006) Preventing end-stage renal disease: flexible strategies to overcome obstacles. Current Opinion in Internal Medicine 5:6, 609-616
CrossRef99
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:2, 103-117
CrossRef100
D Batlle, P Ramadugu, M J Soler. (2006) Progress in retarding the progression of advanced chronic kidney disease: Grounds for optimism. Kidney International 70, S40-S44
CrossRef101
K. A. Pöschel, G. Wolf. (2006) Das Renin-Angiotensin-Aldosteron-System als Zentraler Mediator der Progression der Niereninsuffizienz. Der Nephrologe 1:4, 233-240
CrossRef102
K. Ivens, B. Grabensee. (2006) Zusammenhang zwischen kardiovaskulären Erkrankungen und Progression von Nierenerkrankungen. Der Nephrologe 1:4, 225-232
CrossRef103
Simardeep Mangat, Steven A. Atlas. (2006) Clinical trials report. Current Hypertension Reports 8:6, 443-445
CrossRef104
Mieczysław Litwin, Ryszard Grenda, Joanna Śladowska, Jolanta Antoniewicz. (2006) Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatric Nephrology 21:11, 1716-1722
CrossRef105
Pasquale Zamboli, Luca Nicola, Roberto Minutolo, Valerio Bertino, Fausta Catapano, Giuseppe Conte. (2006) Management of hypertension in chronic kidney disease. Current Hypertension Reports 8:6, 497-501
CrossRef106
S Hirsch. (2006) Renin–angiotensin inhibitors in stage 4 chronic kidney disease. Kidney International 70:10, 1880-1880
CrossRef107
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:1, 8-30
CrossRef108
R Minutolo, M M Balletta, F Catapano, P Chiodini, G Tirino, P Zamboli, G Fuiano, D Russo, P Marotta, C Iodice, G Conte, L De Nicola. (2006) Mesangial hypercellularity predicts antiproteinuric response to dual blockade of RAS in primary glomerulonephritis. Kidney International 70:6, 1170-1176
CrossRef109
Huifang Cheng, Raymond C Harris. (2006) Potential side effects of renin inhibitors – mechanisms based on comparison with other renin–angiotensin blockers. Expert Opinion on Drug Safety 5:5, 631-641
CrossRef110
Anne-Lise Kamper. (2006) Benazepril is renoprotective in patients with severe chronic kidney disease. Nature Clinical Practice Nephrology 2:8, 414-415
CrossRef111
(2006) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 15:6, i-xii
CrossRef112
(2006) Benazepril for Advanced Chronic Renal Insufficiency. New England Journal of Medicine 354:14, 1530-1531
Full Text113
(2006) Journal club. Kidney International 69:6, 950-951
CrossRef114
Karen A. Griffin, Anil K. Bidani. (2006) Hypertension and Kidney Damage. The Journal of Clinical Hypertension 8:3, 209-214
CrossRef115
Jens Gaedeke, Hans-H Neumayer, Harm Peters. (2006) Pharmacological management of renal fibrotic disease. Expert Opinion on Pharmacotherapy 7:4, 377-386
CrossRef116
(2006) The Evolving Chinese Health Care System. New England Journal of Medicine 354:8, 876-876
Full Text117
Hebert, Lee A., . (2006) Optimizing ACE-Inhibitor Therapy for Chronic Kidney Disease. New England Journal of Medicine 354:2, 189-191
Full Text
- Letters
